CHIASSO, Switzerland and Châtillon, France – June 21, 2024 – Farma Mondo Group, a Swiss-based pharmaceutical company, and HRA Pharma Rare Diseases, are pleased to announce the signing of an Exclusive Distribution Agreement for the supply of Lysodren (Mitotane) in Brazil. Under the terms of the agreement, Farma Mondo Group, through its LATAM operations, will manage the access and distribution of Lysodren to Brazilian patients affected by advanced adrenocortical carcinoma through Named Patient Supplies.
About Lysodren
LYSODREN® (Mitotane) is an adrenal cytotoxic agent indicated for the treatment of patients with inoperable Adrenocortical Carcinoma (ACC), an ultra-rare tumor whose incidence is 3 times higher in Brazil.
Yaron Spigel, Group Chief Executive Officer of Farma Mondo, commented: “We are proud to collaborate with HRA Pharma to benefit Lysodren patients in Brazil, ensuring uninterrupted commercial access and distribution services to the market. This partnership highlights Farma Mondo’s commitment to expanding access to essential medications in both emerging and established markets.”
About Farma Mondo Group
Farma Mondo is a fast-growing Swiss group dedicated to providing Biopharma, healthcare professionals and their patients around the world with greater access to medicines, and in the process increasing the value of a pharmaceutical product by extending and expanding its lifecycle. The Group offers high value market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to enable patient access to Specialty Medicines in key Emerging Markets through a combined approach of Named Patient access and full commercialization.
For more details, please visit https://farmamondo.com/
About HRA Pharma
HRA Pharma Rare Diseases is dedicated to bringing the best care and services to people living with rare diseases and is committed to supporting healthcare professionals all over the world.
For more details, please visit https://www.hra-pharma-rare-diseases.com/
